Fig. 4

Cell type-specific TIGIT methylation (CpG5) and mRNA expression. a TIGIT methylation at CpG5 in isolated leukocytes (CD4⁺ T cells [mean methylation: 63.5% [95% CI 60.9–66.2]], CD8⁺ T cells [62.6% [95% CI 58.9–66.3]], B cells [83.8% [95% CI 82.5–85.1]], and monocytes [89.47% [95% CI 88.6–90.3]]) from N = 28 healthy donors, melanocyte (N = 3, 94.8% [95% CI 92.8–96.8]) and melanoma cell lines (N = 59, 90.8% [95% CI 89.2–92.5]). b Single cell TIGIT mRNA expression of different cell subtypes (CD45⁻ [mean expression: 0.0391 TPM [95% CI 0.0202–0.0581], N = 1257 and CD45⁺ cells [2.0649 TPM [95% CI 1.9684–2.1605]], N = 3,256; T cells [3.0444 TPM [95% CI 2.9167–3.1720]], N = 2068; B cells [0.0595 TPM [95% CI 0.0269–0.0920]], N = 515; macrophages [0.0860 TPM [95% CI − 0.0005 to 0.1726]], N = 126) from 19 freshly procured human melanoma samples as previously reported by Tirosh et al. [43]. Bars indicate significant differences (P < 0.05, ANOVA with Bonferroni post-hoc test)